What is HC Wainwright’s Estimate for IPSEN FY2027 Earnings?

IPSEN (OTCMKTS:IPSEY) – Research analysts at HC Wainwright raised their FY2027 earnings per share estimates for IPSEN in a research report issued to clients and investors on Friday, July 31st. HC Wainwright analyst R. Selvaraju now expects that the company will earn $4.20 per share for the year, up from their prior forecast of $4.05. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.84 per share.

A number of other equities analysts also recently weighed in on IPSEY. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Finally, Jefferies Financial Group lowered IPSEN to an “underperform” rating in a report on Sunday. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, IPSEN currently has an average rating of “Hold”.

IPSEN Stock Performance

Shares of OTCMKTS:IPSEY opened at $44.85 on Monday. The stock’s fifty day simple moving average is $45.79 and its two-hundred day simple moving average is $45.61. IPSEN has a 1-year low of $30.05 and a 1-year high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).